Extended Data Fig. 3: BMPs inhibit ACVR1 WT DIPG subtype cells sphere formation and growth.
(a) Immunoblotting analysis of p-SMAD1/5 and SMAD1 levels in TT150630 and TT150714 treated with LDN-193189 (LDN) (200 nM), BMP4 (50 ng/mL), or BMP4 (50 ng/mL) plus LDN-193189 (200 nM). (b) top: Neural sphere formation of the indicated cell lines treated with vehicle, 50 ng/mL BMP2 or 25 ng/mL BMP2 for 10 days, n = 3 independent experiments; bottom: Neural sphere counts from top panel. All p value were generated by comparing to control group. (c) top: Neural sphere formation of the indicated cell lines treated with vehicle or indicated concentration of BMP4 for 10 days, n = 3 independent experiments; bottom: Neural sphere counts from top panel. All p value were generated by comparing to control group.(d) Viability (metabolic capacity) of indicated cells (n = 3 independent experiments) treated with vehicle or indicated concentration of BMP4.(e) Viability (metabolic capacity) of SU-DIPG4 cells (n = 3 independent experiments) treated with vehicle or indicated concentration of BMP4 or LDN. For b-e, data represents the mean ± S.D., statistical significance was calculated by two-tailed unpaired Student’s t-test. The experiments in a have been repeated three times with similar results.
